(Q42286897)

19 October 2017

title

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice (English)

1 reference

19 October 2017

0 references

1 reference

1 reference

1 reference

4

Raviglione MC

1 reference

19 October 2017

2

Truffot-Pernot C

1 reference

19 October 2017

Ji B

1

1 reference

19 October 2017

Lacroix C

3

1 reference

19 October 2017

O'Brien RJ

5

1 reference

19 October 2017

Olliaro P

6

1 reference

19 October 2017

Roscigno G

7

1 reference

19 October 2017

Grosset J

8

1 reference

19 October 2017

publication date

1 December 1993

1 reference

The American Review of Respiratory Disease

19 October 2017

published in

1 reference

19 October 2017

volume

148

1 reference

19 October 2017

issue

6 Pt 1

1 reference

19 October 2017

page(s)

1541-1546

1 reference

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Activityin vitroof Rifabutin, FCE 22807, Rifapentine, and Rifampin againstMycobacterium microtiandM. tuberculosisand Their Penetration into Mouse Peritoneal Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Pharmacokinetics of rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

Intraphagocytic penetration of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F148.6_PT_1.1541

10.1164/AJRCCM/148.6_PT_1.1541

21 January 2018

Identifiers

DOI

0 references

1 reference